According to a story on medicaldialogues.in, a recent study has determined that antifibrotic treatment can reduce the rate of mortality and acute exacerbations in people living with idiopathic pulmonary fibrosis…
A study conducted by researchers at Nagoya University in Japan and researchers from Yale University in the United States was recently published in the European Respiratory Journal. This study utilized single-cell…
As reported in Business Wire; VerSIM Life, a company that uses computational sciences to create novel machine learning to aid drug development, has announced that they are launching a pharmaceutical…
An estimated 13-20 out of every 100,000 people around the globe have idiopathic pulmonary fibrosis (IPF). The condition often has a poor prognosis (3-5 years following diagnosis) and there are…
An estimated 1 in 10 Americans, or 1 in 20 people globally, have or will have a rare disease at some point. Rare Disease Day takes place on February 28. Ultimately,…
Growth differentiation factor 15 (GDF15) is expressed in normal conditions but is overly expressed when cells are under stress. It has multiple roles in different diseases and has been used…
In a recent press release from mid-January 2020, the Pulmonary Fibrosis Foundation (PFF) announced that its registry, the PFF Registry, was being sponsored by biotechnology United Therapeutics. This sponsorship…
Overall, Galapagos works to develop small-molecule treatments for patients with a variety of conditions. In a recent press release, the company reported positive top-line data from the Phase 2 PINTA…
According to a story from GlobeNewswire, the biotechnology company Galecto, Inc., has recently published the results from its phase 2a clinical trial. This study was testing the company's experimental therapy…
Recently, biotherapeutics company PureTech Health announced that their Phase 1 trial to evaluate LYT-100 (deupirfenidone) has completed. During the multiple ascending dose and food effect study, researchers analyzed the safety,…
There is a stigma that comes with the term "palliative care," as it is typically associated with hospice and terminal illnesses. This is not the case, as palliative care is…
United Therapeutics Corporation has recently presented data from the Phase 3 INCREASE trial, which evaluated Tyvaso as a treatment for pulmonary hypertension associated with interstitial lung disease. Results were presented…
Cynata Therapeutics Limited has recently announced the results from their preclinical trial of induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal stem cells (MSCs), according to BioSpace. They are testing these…
According to a story from Newswise, September is recognized as Pulmonary Fibrosis Awareness Month. This includes idiopathic pulmonary fibrosis (IPF), or disease without an identifiable cause. In the midst of…
A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…
Idiopathic Pulmonary Fibrosis Progression Veracyte has just signed a deal with Yale University which will help them develop the very first test which can predict disease progression for idiopathic pulmonary…
Predicting the disease progression of idiopathic pulmonary fibrosis (IPF) is extremely important, as this condition progresses differently depending on the affected individual. Knowing if one has a poor outcome while…
As stated in a press release from the University of Illinois at Urbana-Champaign, researchers have discovered a bacterial protein fragment that is destructive to lung tissue. This can rapidly…
According to a story from Medical Xpress, a recent study has concluded that characteristics of a patient's lung microbiome can help predict treatment outcomes, particular in patients with severe lung…
According to a story from mHealth Intelligence, the University of Alabama has found success with using telehealth to check in with kidney disease patients that are on dialysis. Now, it…
According to a story from EurekAlert!, a collaborative study headed by researchers from Yale University has furthered the understanding of the mechanisms and progression of fibrosis (scarring) in patients with…
According to a story from PR Newswire, the National Institutes of Health (NIH) and Three Lakes Partners have awarded a grant to the tune of $22 million to the Pulmonary…
According to a publication from Scleroderma News, the American Food and Drug Administration (FDA) recently granted Breakthrough Therapy status to Ofev (generic name nintedanib), as a treatment for progressive fibrosing…
According to a story from Financial Buzz, the biotherapeutics company Bellerophon Therapeutics Inc. has recently announced that it has earned Orphan Drug designation from the US Food and Drug Administration…
According to a story from finanzen.at, the drug nintedanib (marketed as Ofev) has officially been approved by the US Food and Drug Administration (FDA) as a treatment for interstitial lung…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
